T-Therapeutics raises $133M to push cancer, autoimmune therapies into the clinic
What's the deal? UK biotech T-TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised an oversubscribed $133 million Series B to fund two first-in-class TCR-CD3 bispecific programmes in cancer and autoimmune disease. Advent Life SciencesDealroom has a profile for this one. Try Dealroom → and the British Business Bank co-led the round, announced November 5, 2026.
Who's backing it? New investors include Johnson & JohnsonDealroom has a profile for this one. Try Dealroom → Innovation – JJDC, Samsara BioCapitalDealroom has a profile for this one. Try Dealroom →, M-VenturesDealroom has a profile for this one. Try Dealroom →, and Eli LillyDealroom has a profile for this one. Try Dealroom →. All existing major shareholders joined too, among them Sofinnova Partners, F-Prime, Digitalis VenturesDealroom has a profile for this one. Try Dealroom →, Cambridge Innovation CapitalDealroom has a profile for this one. Try Dealroom →, Sanofi VenturesDealroom has a profile for this one. Try Dealroom →, Tencent, and BGF.
What's the endgame? The Cambridge-based company is developing next-generation T cell receptor therapeutics built on its OpTiMus platform, which it says can reach validated but previously undruggable intracellular targets. The money will take both lead programmes through to clinical proof-of-concept.
Why now? The round marks a step-up from T-Therapeutics' $91 million Series A, completed in 2025, and funds its transition to a clinical-stage company. It also appointed Kirsty Crame as chief development officer to oversee clinical development.
Chief executive officer Theodora Harold called the financing "a key step in our transition to a clinical-stage company."
What could go wrong? Both programmes remain preclinical. The therapies have yet to be tested in humans, so clinical data — not the "first-in-class" label — will decide whether the approach stands out.
The signal: The round reflects sustained appetite for T-cell-engager approaches in the UK, where London-based Cytospire raised $83 million in May 2026 for a distinct platform. The scale of the backing, from big pharma and new life-sciences funds alike, signals confidence as these companies move from preclinical promise toward human data.
Read more: endpoints.news
Image credit: Generated with Gemini
